- Home
- BAP vs RPRX Comparison
BAP vs RPRX Comparison
Compare BAP & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BAP | RPRX |
|---|---|---|
| Founded | 1889 | 1996 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 16.2B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BAP | RPRX |
|---|---|---|
| Price | $272.76 | $39.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $260.17 | $46.00 |
| AVG Volume (30 Days) | 316.1K | ★ 4.3M |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | ★ 4.04% | 2.21% |
| EPS Growth | ★ 24.08 | N/A |
| EPS | ★ 23.44 | 1.75 |
| Revenue | ★ $5,896,627,147.00 | $2,349,844,000.00 |
| Revenue This Year | $24.38 | $37.13 |
| Revenue Next Year | $7.81 | $1.48 |
| P/E Ratio | ★ $11.62 | $22.68 |
| Revenue Growth | ★ 19.24 | 3.70 |
| 52 Week Low | $165.51 | $24.05 |
| 52 Week High | $280.88 | $41.24 |
Technical Indicators
Market Signals| Indicator | BAP | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.51 | 57.50 |
| Support Level | $240.00 | $39.24 |
| Resistance Level | $258.10 | $40.50 |
| Average True Range (ATR) | 7.28 | 0.91 |
| MACD | 2.51 | -0.08 |
| Stochastic Oscillator | 80.77 | 76.02 |
Price Performance
Historical ComparisonAbout BAP Credicorp Ltd.
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.